ClinicalTrials.gg

Diabetes Mellitus, Type 1 clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,755 studies for Diabetes Mellitus, Type 1 across more than 10 countries. 600 are recruiting or about to start. 3,346 of them are mainly about Diabetes Mellitus, Type 1 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 4,678 studies for Diabetes Mellitus, Type 1. How that becomes 3,754 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Diabetes Mellitus, Type 1, and those it files under no condition that list Diabetes Mellitus, Type 1themselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 4,678Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −70List Diabetes Mellitus, Type 1 as a condition, but the registry did not file them under itMost often written as “Type1diabetes” (27), “Diabete Type 1” (9), and “Type1 Diabetes Mellitus” (8). The registry filed them under other conditions only, most often Diabetes Mellitus (22) and Hypoglycemia (14).
  3. −892Match it another way157 name it in the title, 5 in a keyword, and 730 by a synonym or other text the search reads.
  4. 3,716Counted here and found by its search143 of them list Diabetes Mellitus, Type 1 in their own words; the registry filed them under no condition.
  5. +38
    Counted here, but its search does not find themThe first 20 of 38.
  6. 3,754The count on this page

Status

Completed
2,417
Recruiting
415
Status unknown
261
Terminated
205
Not yet recruiting
155
Active, not recruiting
135

Phase

Phase 2
534
Phase 1
439
Phase 3
320
Phase 4
197
Early Phase 1
57

Where

United States
1,458
Canada
319
Germany
294
France
271
United Kingdom
268
Denmark
196

Who develops what

Add Diabetes Mellitus, Type 1 to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 23 companies, 29 with this as their studies’ main aim; 6 with a live phase 3 study; 11 primary completions in the next 12 months. Compare Novo Nordisk, Eli Lilly and Mannkind here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Insulin GlargineRecent, repeated
Evidence
  • NCT07282054 · Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3 · background · “Insulin Glargine” · registered Dec 2025
  • NCT07076199 · Novo Nordisk A/S · Phase 3 · live · comparator · “Insulin glargine” · registered Jul 2025
  • NCT07070752 · Geropharm · Phase 3 · background · “RinGlar®” · registered Jul 2025
  • NCT04974528 · Mannkind Corporation · Phase 3 · background · “Basal Insulin” · registered Jun 2021
  • NCT04022993 · Geropharm · Phase 3 · comparator · “Lantus Solostar, 100 Units/mL Subcutaneous Solution” · registered Jul 2019
Sanofi65% of its industry studiesUS: Sanofi (FDA 2000) + 3 othersEU: Sanofi (EMA 2000) + 3 others33 studies
Insulin LisproRecent, repeated
Evidence
  • NCT07282054 · Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3 · comparator · “Insulin Lispro” · registered Dec 2025
  • NCT06238778 · Diasome Pharmaceuticals · Phase 2 · comparator · “Lispro” · registered Jan 2024
  • NCT04816890 · Adocia · Phase 2 · comparator · “Insulin lispro” · registered Mar 2021
  • NCT04254380 · Gan & Lee Pharmaceuticals · Phase 3 · comparator · “Humalog” · registered Jan 2020
  • NCT03156361 · Diasome Pharmaceuticals · Phase 2 · comparator · “Insulin Lispro 100 Units/mL” · registered May 2017
Eli Lilly and Company67% of its industry studiesUS: Eli Lilly and Company (FDA 1999) + 1 otherEU: Eli Lilly and Company (EMA 1996) + 2 others22 studies
GlucagonRecent, repeated
Evidence
  • NCT06588504 · Novo Nordisk A/S · Phase 3 · background · “Glucagon” · registered Sep 2024
  • NCT05454709 · Inreda Diabetic B.V. · Phase 2 · comparator · “GlucaGen” · registered May 2022
  • NCT03378635 · Zealand Pharma · Phase 3 · comparator · “GlucaGen” · registered Dec 2017
  • NCT02971228 · Zealand Pharma · Phase 2 · background · “Glucagon” · registered Nov 2016
  • NCT02916251 · Zealand Pharma · Phase 2 · comparator · “Glucagon (Native glucagon)” · registered Sep 2016
Eli Lilly and Company42% of its industry studiesUS: Amphastar Pharmaceuticals, Inc. (FDA 2019) + 1 otherEU: Amphastar Pharmaceuticals, Inc. (EMA 2019) + 1 other22 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TirzepatideApproved: US 2022 · EU 2022☆ Track2 live phase-3 studies: NCT06914895, NCT06962280Eli Lilly and Company
insulin icodecApproved: EU 2024☆ Track1 live phase-3 study: NCT07076199Novo Nordisk A/S
cadisegliatin☆ Track1 live phase-3 study: NCT06334133vTv Therapeutics
teplizumabApproved: EU 2026☆ Track1 live phase-3 study: NCT07088068Sanofi
baricitinibApproved: US 2018 · EU 2017☆ Track2 live phase-3 studies: NCT07222137, NCT07222332Eli Lilly and Company

The 5 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (11)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.Tirzepatide · Eli Lilly and Company · Phase 3 main aimNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight — primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c) · 905 enrolled
  • Nov 2026 est.Tirzepatide · Eli Lilly and Company · Phase 3 main aimNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight — primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c) · 465 enrolled
  • 25 Jan 2027 est.insulin icodec · Novo Nordisk A/S · Phase 3 main aim+ Insulin aspart vs Insulin Glargineadded to Insulin AspartNCT07076199 A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes — primary endpoint: Change in glycosylated haemoglobin (HbA1c) · 877 enrolled

8 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetes Mellitus, Type 1 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 19 open · SGLT2 inhibitors 9 open · Calcium channel blockers 5 open · Tyrosine kinase inhibitors (TKIs) 4 open · JAK inhibitors 3 open

Coming up

245studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger. 187 (45%) take children under 18. 15 (4%) are for women only and 3 (1%) for men only; 65 (16%) take healthy volunteers.

Recruiting studies that take each age, of 415
AgeWomenMen
10139 (33%)138 (33%)
18342 (82%)333 (80%)
30291 (70%)283 (68%)
40280 (67%)272 (66%)
50259 (62%)252 (61%)
65228 (55%)220 (53%)
75178 (43%)170 (41%)
85147 (35%)141 (34%)

Across all 3,755 studies, recruiting or not: 67% stop at 75 or younger and 57% at 65; 40% take children; 2% are for women only and 2% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetes Mellitus, Type 1 studies take

Of 152 phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo5–32 · 152 studies7 mo4–13 · 97 studies37 mo18–64 · 55 studies
Phase 1/257 mo31–93 · 44 studies——
Phase 236 mo17–63 · 134 studies19 mo8–33 · 51 studies51 mo31–76 · 83 studies
Phase 2/323 mo12–41 · 19 studies——
Phase 318 mo10–27 · 108 studies17 mo9–24 · 79 studies—
Phase 422 mo12–38 · 74 studies—25 mo13–46 · 62 studies
Interventional, no phase18 mo9–35 · 953 studies10 mo5–18 · 105 studies19 mo10–38 · 848 studies
Observational30 mo12–69 · 299 studies22 mo12–42 · 50 studies30 mo12–78 · 249 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,755. Browse all 3,755 → or search them.